Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Last trade$1.38
Day change-$0.035 (-2.48%)
Day range$1.35 – $1.49
Volume30,798
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.37M
Price / earnings
—
Price / book
0.67×
Price / sales
6.76×
EV / sales
-1.48×
EV / EBITDA
0.05×
Profitability
Earnings per share
-$4.61
Return on assets
-71.26%
Return on equity
-219.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.65×
Quick ratio
1.65×
Cash ratio
0.84×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.97M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MCRB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$593K
$736K
$358K
$438K
$351K
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$593K
$736K
$358K
$438K
$351K
$0
$0
$0
Selling, general and administrative
$5.45M
$7.06M
$8.07M
$7.54M
$9.48M
$10.25M
$11.89M
$12.46M
Research and development
$5.59M
$9.14M
$13.2M
$11.68M
$12.62M
$12.94M
$11.82M
$12.84M
Total operating expenses
$16.75M
$22.01M
$21.27M
$19.82M
$22.83M
$24.88M
$27.24M
$28.84M
Operating income
-$16.15M
-$21.27M
-$20.91M
-$19.38M
-$22.48M
-$24.88M
-$27.24M
-$28.84M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$16.29M
$4.58M
-$19.91M
-$15.34M
$8.2M
-$19.86M
$32.68M
-$15.64M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$16.29M
$4.58M
-$19.91M
-$15.34M
$8.2M
-$19.86M
$32.68M
-$15.64M
Net income attributable to common shareholders
-$16.29M
$4.58M
-$19.91M
-$15.34M
$8.2M
-$19.86M
$32.68M
-$15.64M
EBITDA
-$9.97M
-$14.8M
-$20.13M
-$18.42M
-$21.43M
-$23.82M
-$26.16M
-$27.75M
Basic earnings per share
-$1.63
$0.47
-$2.08
-$1.66
$0.94
-$2.27
$3.76
-$1.83
Diluted earnings per share
-$1.63
$0.47
-$2.08
-$1.66
$0.94
-$2.27
$3.75
-$1.83
Recent news
Company coverage with links to the original publishers.
Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding.
Seres Therapeutics granted stock options to purchase 4,200 shares to two new employees on September 4, 2026, with an exercise price of $5.72 per share under its 2022 Employment Inducement Award Plan. The options vest 25% on the first anniversary and 6.25% quarterly thereafter.
Seres Therapeutics announced three presentations at the 2026 ESCMID congress highlighting Phase 1b data for SER-155, a live biotherapeutic candidate. The data demonstrated that SER-155 induced significant and durable shifts in GI microbiome composition with improved epithelial barrier integrity, correlating with reduced bloodstream infections in allogeneic hematopoietic cell transplant patients. Additional presentations explored the role of live biotherapeutics in IBD and immunocompromised patients.
Seres Therapeutics reported a net income of $5.7 million for full year 2025 compared to a net loss of $125.8 million in 2024, primarily driven by gains from the VOWST sale to Nestlé and reduced operating expenses. The company is prioritizing development of SER-155 for immune checkpoint-related enterocolitis and SER-603 for inflammatory bowel disease, with clinical data from an investigator-sponsored trial expected in Q2 2026. With $45.8 million in cash, Seres expects to fund operations through Q3 2026 and is actively seeking partnerships and additional funding to advance its pipeline.
The human microbiome market is expected to grow from $0.85 billion in 2026 to $3.27 billion by 2035, driven by advancements in sequencing technologies, rising R&D investments, and increasing demand for personalized medicine. Currently, approximately 215 microbiome therapeutics are in development across various stages, with over 50% in clinical stages. North America is expected to dominate the market, supported by regulatory approvals and strategic partnerships.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.